Crinetics Pharmaceuticals (CRNX) Receivables - Accured (2022 - 2026)

Crinetics Pharmaceuticals' Receivables - Accured history runs 5 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• In Q1 2026, Receivables - Accured rose 25.0% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $9.0 million (up 25.0% YoY), while the FY2025 annual figure was $7.8 million, down 6.02% from the prior year.
• Receivables - Accured was $9.0 million for Q1 2026 at Crinetics Pharmaceuticals, up from $7.8 million in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $9.0 million in Q1 2026 to a low of $1.4 million in Q4 2022.
• Historically, Receivables - Accured has averaged $6.4 million across 5 years, with a median of $7.5 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Receivables - Accured surged 167.74% in 2024, then decreased 6.02% in 2025.
• A 5-year view of Receivables - Accured shows it stood at $1.4 million in 2022, then soared by 121.43% to $3.1 million in 2023, then soared by 167.74% to $8.3 million in 2024, then declined by 6.02% to $7.8 million in 2025, then gained by 15.38% to $9.0 million in 2026.
• The last three Receivables - Accured figures came in at $9.0 million (Q1 2026), $7.8 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.